Prevalence of adverse drug reaction with first-line drugs among patients treated for pulmonary tuberculosis
Tóm tắt
Từ khóa
Tài liệu tham khảo
Forget, 2006, Adverse reactions to first-line anti-tuberculosis drugs, Expert Opin Drug Saf, 5, 231, 10.1517/14740338.5.2.231
Gülbay, 2006, Side effects due to primary anti-tuberculosis drugs during the initial phase of therapy in 1149 hospitalized patients for tuberculosis, J Respir Med, 10, 1834, 10.1016/j.rmed.2006.01.014
Tan, 2007, Two years review of cutaneous adverse drug reaction from first line anti-tuberculous drugs, Med J Malaysia, 62, 143
World Health Organization, 2014
World Health Organization, 1975
Edwards, 2000, Adverse drug reactions: definitions, diagnosis, and management, Lancet, 356, 1255, 10.1016/S0140-6736(00)02799-9
Brasil. Ministério da Saúde. Fundação Nacional de Saúde. Centro de Referência Professor Hélio Fraga; Sociedade Brasileira de Pneumologia e Tisiologia. Controle da tuberculose: uma proposta de integração ensino-serviço. Rio de Janeiro: FUNASA/CRPHF/SBPT; 2002.
Dosumu, 2002, Side effects of drugs used in directly observed treatment short-course in newly diagnosed pulmonary tuberculosis subjects in Nigerian's: a controlled clinical study, Niger Post Grad Med J, 9, 34, 10.4103/1117-1936.171023
Yee, 2003, Incidence of serious side effects from first-line anti-tuberculosis drugs among patients treated for active tuberculosis, Am J Respir Crit Care Med, 167, 1472, 10.1164/rccm.200206-626OC
Dhingra, 2004, Adverse drug reactions observed during DOTS, J Commun Dis, 36, 251
Gholami, 2006, Evaluation of anti-tuberculosis induced adverse reactions in hospitalized patients, Pharm Pract, 4, 134
Taher, 2006, DOTS at a tertiary care centre in northern India: scenario challenges and next step in TB control, Ind J Med Res, 123, 702
Chhetri, 2008, A study of adverse drug reactions caused by first line anti-tubercular drugs used in Directly Observed Treatment, Short course (DOTS) therapy in western Nepal, Pokharan, J Pak Med Assoc, 58, 531
Kishore, 2008, Pattern of adverse drug reactions experienced by tuberculosis patients in a tertiary care teaching hospital in Western Nepal Pak, J Pharm Sci, 21, 51
Tak, 2009, Safety evaluation of anti-tubercular therapy under revised national tuberculosis control programme in India, J Clin Diagn Res, 3, 1395
Jeong, 2009, The influence of adverse drug reactions on first-line anti-tuberculosis chemotherapy in the elderly patients, Tuberc Respir Dis, 67, 325, 10.4046/trd.2009.67.4.325
Maciel, 2010, Adverse effects of the new tuberculosis treatment regimen recommended by the Brazilian National Ministry of Health, J Bras Pneumol, 36, 232, 10.1590/S1806-37132010000200012
Kurniawati, 2012, Adverse drug reactions of primary anti-tuberculosis drugs among tuberculosis patients treated in chest clinic, Int J Pharm Life Sci, 3, 1331
Lv, 2013, Adverse reactions due to directly observed treatment strategy therapy in Chinese tuberculosis patients: a prospective study, PLOS ONE, 8, e65037, 10.1371/journal.pone.0065037
Sinha, 2013, Adverse drug reactions in tuberculosis patients due to directly observed treatment strategy therapy: experience at an outpatient clinic of a teaching hospital in the city of Imphal, Manipur, Indian J Assoc Chest Phys, 1, 50, 10.4103/2320-8775.123213
Qureshi, 2013, Adverse effects of first line anti-tuberculosis drugs in patients on DOTS CAT1 under revised national tuberculosis control programme (RNTCP), IJBPAS, 2, 2267
Mandal, 2013, Comparing the daily versus the intermittent regimens of the anti-tubercular chemotherapy in the initial intensive phase in non-HIV, sputum positive, pulmonary tuberculosis patients, J Clin Diagn Res, 7, 292
Dalal, 2014, Safety evaluation of directly observed treatment short course (DOTS) regimen in a tertiary care hospital, Pune, Int J Basic Clin Pharmacol, 3, 369, 10.5455/2319-2003.ijbcp20140423
Verma, 2014, Adverse drug reactions associated with first line anti-tubercular drugs in a tertiary care hospital of central India: a study of clinical presentations, causality, and severity, Asian J Pharm Clin Res, 7, 140
Farazi, 2014, Adverse reactions to anti-tuberculosis drugs in Iranian tuberculosis patients, Tuberc Res Treat
Sivaraj, 2014, Revised National Tuberculosis Control Program regimens with and without directly observed treatment, short-course: a comparative study of therapeutic cure rate and adverse reactions, Perspect Clin Res, 5, 16, 10.4103/2229-3485.124557
Athira, 2015, A study on adverse drug reactions to first line anti-tubercular drugs in DOTS therapy, Int J Pharmacol Clin Sci, 4, 7
Breen, 2006, Adverse events and treatment interruption in tuberculosis patients with and without HIV co-infection, Thorax, 61, 791, 10.1136/thx.2006.058867
Hong Kong Chest Services/BMRC, 1978, Controlled trial 6-month and 8-month regimen in the treatment of pulmonary tuberculosis. 1st report, Am Rev Resp Dis, 118, 219
Arbex, 2010, Anti-tuberculosis drugs: drug interactions, adverse effects, and use in special situations. Part 1: first-line drugs, J Bras Pneumol, 36, 626, 10.1590/S1806-37132010000500016
Vieira, 2008, Adverse effects of tuberculosis treatment: experience at an outpatient clinic of a teaching hospital in the city of São Paulo, Brazil, J Bras Pneumol, 34, 1049, 10.1590/S1806-37132008001200010
Singapore Tuberculous Service/BMRC, 1979, Clinical trial of six month and four month regimen of chemotherapy in the TB of pulmonary tuberculosis. 1st report, Am Rev Resp Dis, 579, 119
Mwandumba, 2005
Mehrotra, 1982, Agra study of short course chemotherapy in pulmonary tuberculous patients, Indian J Tuberc, 29, 29
Shinde, 2013, Adverse reactions to first-line anti-tuberculous agents in hospitalised patients: pattern, causality, severity and risk factors, Indian J Med Spec, 4, 1
Anand, 2006, Risk factors of hepatotoxicity during anti-tuberculosis treatment, MJAFI, 62, 45
Parthasarathy, 1986, Hepatic toxicity in south Indian patients during treatment of tuberculosis with short-course regimens containing isoniazid, rifampicin and pyrazinamide, Tubercle, 67, 99, 10.1016/0041-3879(86)90003-6
Purohit, 1983, Tuberc Rifampicin and hepatic toxicity, Indian J Tuberc, 30, 107
Blumberg, 2003, American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis, Am J Respir Crit Care Med, 167, 603, 10.1164/rccm.167.4.603
Steele, 1971, Hepatitis with isoniazid and rifampicin – a meta analysis, Chest, 99, 465, 10.1378/chest.99.2.465
Gangadharan, 1986, Isoniazid, rifampicin and hepatotoxicity, Am J Respir Dis, 133, 963
Pande, 1996, Risk factors for hepatotoxicity from antituberculous drugs: a case control study, Thorax, 51, 132, 10.1136/thx.51.2.132
Baghaei, 2010, Incidence, clinical and epidemiological risk factors, and outcome of drug-induced hepatitis due to antituberculous agents in new tuberculosis cases, Am J Ther, 17, 17, 10.1097/MJT.0b013e31818f9eae
Lee, 2002, Risk factors for hepatotoxicity associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection: experience from three public health tuberculosis clinics, Int J Tuberc Lung Dis, 6, 995
Nakajo, 1989, Incidence of hepatotoxicity in children receiving isoniazid chemoprophylaxis, Pediatr Infect Dis J, 8, 649, 10.1097/00006454-198909000-00019
O’Brien, 1983, Hepatotoxicity from isoniazid and rifampin among children treated for tuberculosis, Pediatrics, 72, 491, 10.1542/peds.72.4.491
Durand, 1995, Deleterious influence of pyrazinamide on the outcome of patients with fulminant or subfulminant liver failure during antituberculous treatment including isoniazid, Hepatology, 21, 929, 10.1002/hep.1840210407
Shakya, 2004, Incidence of hepatotoxicity due to antitubercular medicines and assessment of risk factors, Ann Pharmacother, 38, 1074, 10.1345/aph.1D525
Khadka, 2009, The study of drug induced hepatotoxicity in ATT patients attending in National Tuberculosis Center in Bhaktapur, SAARC, J Tuber Lung Dis HIV/AIDS, 2, 17
Mahmood, 2007, Hepatotoxicity with antituberculosis drugs: the risk factors, Pak J Med Sci, 23, 33
Maria de Fátima Silva, 2012, Hepatotoxicity induced by antituberculosis drugs among patients coinfected with HIV and tuberculosis, Cad Saúde Pública, 28, 698, 10.1590/S0102-311X2012000400009
Singla, 2010, Evaluation of risk factors for antituberculosis treatment-induced hepatotoxicity, Indian J Med Res, 132, 81
Sharma, 2002, Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment, Am J Respir Crit Care Med, 166, 916, 10.1164/rccm.2108091
Singh, 1996, Hepatotoxicity due to antituberculosis therapy: clinical profile and reintroduction of therapy, J Clin Gastroenterol, 22, 211, 10.1097/00004836-199604000-00012
Sanyal, 2003, Acute liver failure, 445
Kumar, 2010, Anti-tuberculosis therapy-induced acute liver failure: magnitude, profile, prognosis, and predictors of outcome, Hepatology, 51, 1665, 10.1002/hep.23534
Koju, 2005, Occurrence of side effects from anti-tuberculosis drugs in urban Nepalese population under DOTS treatment, Kathmandu Univ J Sci Eng Technol, 1
Prasad, 2008, Isoniazid- and ethambutol-induced psychosis, Ann Thorac Med, 3, 149, 10.4103/1817-1737.43083
Cohn, 1957, Serum isoniazid levels and catalase activities of tubercle bacilli from isoniazid-treated patients, Am J Med Sci, 233, 66, 10.1097/00000441-195701000-00011
Agarwala, 1975, Toxic psychosis due to isoniazid, Indian J Tuberc, 3, 119
Bedi, 1994, Isoniazid induced pyrexia and psychosis in a single individual, Indian J Tuberc, 41, 269
Tiwari, 1997, Homicide by a tuberculous prisoner possibly having drug Induced acute delusional psychosis, Indian J Tuberc, 44, 95
Thundiyil, 2007, Evolving epidemiology of drug-induced seizures reported to a Poison Control Center System, J Med Toxicol, 3, 15, 10.1007/BF03161033
Weidorn, 1954, Schizophrenic-like psychotic reaction with administration of isoniazid, Arch Neurol Psychiatr, 72, 321, 10.1001/archneurpsyc.1954.02330030055005
Bonilla, 2000
Carr, 1962, Ocular manifestations of ethambutol, Arch Ophthalmol, 67, 566, 10.1001/archopht.1962.00960020566009
Tsai, 1997, Reversibility of ethambutol optic neuropathy, J Ocul Pharmacol Ther, 13, 473, 10.1089/jop.1997.13.473
Leibold, 1966, The ocular toxicity of ethambutol and its relation to dose, Ann N Y Acad Sci, 135, 904, 10.1111/j.1749-6632.1966.tb45532.x
Moore, 1984, Risk factors for the development of auditory toxicity in patients receiving aminoglycosides, J Infect Dis, 149, 23, 10.1093/infdis/149.1.23
Prrazic, 1975, Ototoxicity in children caused by streptomycin, Audiology, 14, 173, 10.3109/00206097509071734
Robinson, 1964, Hearing loss in infants of tuberculous mothers treated with streptomycin during pregnancy, N Eng J Med, 271, 949, 10.1056/NEJM196410292711808
Johnsonbaugh, 1974, Familial occurrence of drug induced hearing loss, Am J Dis Child, 127, 245
Indian Council of Medical Research Centre Report, 1983, Study of Chemotherapy regimens of 5 and 7 months duration and the role of corticosteroids in the treatment of Sputum-positive patients with pulmonary tuberculosis in South India, Tubercle, 64, 73, 10.1016/0041-3879(83)90032-6
Berte, 1964, Isoniazid, paraaminosallicylic acid and streptomycin intolerance in 1,744 patients, Am Rev Resp Dis, 90, 598
Neff, 1969, Incidence of drug intolerance to antituberculosis chemotherapy, Dis Chest, 56, 10, 10.1378/chest.56.1.10
Rybak, 1999, Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity, Antimicrob Agents Chemother, 43, 1549, 10.1128/AAC.43.7.1549
Kant, 2010, Pyrazinamide induced thrombocytopenia, Indian J Pharmacol, 42, 108, 10.4103/0253-7613.64495
Garg, 2007, Rifampicin induced thrombocytopenia, Indian J Tuberc, 54, 94
Prasad, 1989, Rifampicin induced thrombocytopenia, Indian J Tuberc, 36, 171
Gerdan, 2013, Paradoxical increase in uric acid level with allopurinol use in pyrazinamide-induced hyperuricemia, Singapore Med J, 54, e125, 10.11622/smedj.2013097
Gutman, 1969, Renal function in gout. III. Estimation of tubular secretion and reabsorption of uric acid by use of pyrazinamide (pyrazinoic acid), Am J Med, 47, 575
Postlethwaite, 1972, Hyperuricemia due to ethambutol, N Engl J Med, 286, 761, 10.1056/NEJM197204062861407
Rougier, 2003, Aminoglycoside nephrotoxicity: modeling, simulation, and control, Antimicrob Agents Chemother, 47, 1010, 10.1128/AAC.47.3.1010-1016.2003
de Jager, 2002, Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis, Int J Tuberc Lung Dis, 6, 622
Tawanda, 2011, 1559
Vedove, 2009, Drug-induced lupus erythematosus, Arch Dermatol Res, 301, 99, 10.1007/s00403-008-0895-5
Garg, 2008, Exfoliative dermatitis secondary to ethambutol and pyrazinamide, Internet J Pulm Med, 9, 1
Rakotoson, 2009, Severe systemic lupus erythematosus induced by isoniazid [Article in French], Rev Pneumol Clin, 65, 361, 10.1016/j.pneumo.2009.08.006
Garg, 2009, Isoniazid induced gynaecomastia: a case report, Indian J Tuberc, 56, 51
Khan, 2012, Isoniazid related gynaecomastia: description of a case and systematic review of literature, Lung India, 29, 189, 10.4103/0970-2113.95343
Prasad, 1989, Anaphylactic shock due to streptomycin sulphate, J Indian Med Assoc, 82, 254